Skip to main content

Table 2 Clinical characteristics of different PD-L1 expression cohorts in LUAD and LUSC

From: Comprehensive characterization of PD-L1 expression and immunotherapy-related genomic biomarkers in early- versus advanced-stage non-small cell lung cancer

PD-L1 expression level

LUAD (n = 2476)

I-III (n = 811)

 

IV (n = 1665)

 

High(n = 61)

Low(n = 270)

Negative

(n = 480)

P

High(n = 266)

Low(n = 582)

Negative

(n = 817)

P

n (%)

n (%)

n (%)

 

n (%)

n (%)

n (%)

 

Age (median, range)

64 (26–82)

61 (11–84)

61 (25–85)

0.037

61 (29–90)

61 (28–90)

61 (28–90)

0.493

Sex

 

< 0.001

 

< 0.001

Male

43 (70.49)

149 (55.19)

201 (41.88)

 

179 (67.29)

311 (53.44)

412 (50.43)

 

Female

18 (29.51)

121 (44.81)

279 (58.13)

87 (32.71)

271 (46.56)

405 (49.57)

Smoking status

 

< 0.001

 

< 0.001

Ever

17 (27.87)

61 (22.59)

76 (15.83)

 

85 (31.95)

140 (24.05)

183 (22.40)

 

Never

20 (32.79)

140 (51.85)

299 (62.29)

108 (40.60)

308 (52.92)

441 (53.98)

Unknown

24 (39.34)

69 (25.56)

105 (21.88)

73 (27.44)

13 (23.02)

193 (23.62)

PD-L1 expression level

LUSC (n = 523)

I-III (n = 120)

 

IV (n = 403)

 

High(n = 22)

Low(n = 63)

Negative

(n = 35)

P

High(n = 84)

Low(n = 163)

Negative

(n = 156)

P

n (%)

n (%)

n (%)

 

n (%)

n (%)

n (%)

 

Age (median, range)

62 (33–75)

62 (35–85)

61 (44–81)

0.1276

61 (32–87)

61 (30–85)

62 (40–84)

0.5766

Sex

 

0.6770

 

0.5475

Male

20 (90.91)

59 (93.65)

31 (88.57)

 

72 (85.71)

145 (88.96)

141 (90.38)

 

Female

2 (9.09)

4 (6.35)

4 (11.43)

12 (14.29)

18 (11.04)

15 (9.62)

Smoking status

 

0.6422

 

0.7484

Ever

19 (86.36)

56 (88.89)

30 (85.71)

 

67 (79.76)

132 (80.98)

125 (80.13)

 

Never

2 (9.09)

4 (6.35)

1 (2.86)

8 (9.52)

22 (13.50)

19 (12.18)

Unknown

1 (4.55)

3 (4.76)

4 (11.43)

9 (10.71)

9 (5.52)

12 (7.69)